Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00044408 |
The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
Condition | Intervention | Phase |
---|---|---|
Diabetic Neuropathies Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus, Non-Insulin-Dependent |
Drug: Ruboxistaurin mesylate |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes |
Estimated Enrollment: | 200 |
Study Start Date: | July 2002 |
Study Completion Date: | October 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Study ID Numbers: | 6204, B7A-MC-MBCW |
Study First Received: | August 28, 2002 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00044408 |
Health Authority: | United States: Food and Drug Administration |
Metabolic Diseases Autoimmune Diseases Diabetic Neuropathies Diabetes Mellitus Endocrine System Diseases Diabetes Mellitus, Type 1 Neuromuscular Diseases |
Ruboxistaurin Peripheral Nervous System Diseases Diabetes Mellitus, Type 2 Endocrinopathy Glucose Metabolism Disorders Metabolic disorder Diabetes Complications |
Molecular Mechanisms of Pharmacological Action Immune System Diseases Nervous System Diseases Enzyme Inhibitors Pharmacologic Actions |